drugset / Trial / NCT05498545
Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma
Phase 1
Terminated
8 enrolled
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Universal BCMA-targeted LUCAR-B68 Cells Product in Patients With Relapsed/Refractory Multiple Myeloma
Timeline
- Start
- 2022-11-24
- Primary completion
- 2025-05-30
- Completion
- 2025-05-30
Outcome
Outcome not reported
Stopped: “Achieved the proof of concept”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LUCAR-B68 | Cell therapy | — | — |